Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
It promises fewer injections for vision loss patients
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
Subscribe To Our Newsletter & Stay Updated
